论文部分内容阅读
目的探讨新辅助化疗对乳腺癌患者远、近期疗效及Ki-67表达的影响。方法乳腺癌患者160例,依据化疗方法分为常规组和新疗组,每组80例,常规组患者给予常规化疗(85 mg/m2表柔比星),新疗组患者给予新辅助化疗(TEC方案),采用免疫组化检测Ki-67。随访3年,分析所有患者疗效、生存预后及化疗前、手术后Ki-67表达情况。结果新疗组患者有效率明显高于常规组(P<0.05),手术后Ki-67表达阳性率明显低于常规组(P<0.05),1、2、3年累积生存率明显高于常规组;Ki-67阳性患者1、2、3年累积生存率明显低于阴性患者(P<0.05)。结论新辅助化疗可有效提高乳腺癌患者的远、近期疗效,降低患者体内Ki-67表达,且化疗后Ki-67表达可能与患者生存预后有密切关联,对化疗结局有一定的指示作用。
Objective To investigate the effect of neoadjuvant chemotherapy on the long-term and short-term efficacy and Ki-67 expression in patients with breast cancer. Methods One hundred and sixty breast cancer patients were divided into routine and neoadjuvant groups according to the chemotherapy regimen, 80 cases in each group. Conventional chemotherapy (85 mg / m2 epirubicin) was given to patients in routine group and neoadjuvant chemotherapy TEC program), using immunohistochemical detection of Ki-67. All patients were followed up for 3 years to analyze the curative effect, prognosis and Ki-67 expression before and after chemotherapy. Results The effective rate of the new treatment group was significantly higher than that of the conventional group (P <0.05). The positive rate of Ki-67 expression in the new treatment group was significantly lower than that in the conventional group (P <0.05), and the cumulative survival rate at 1, 2 and 3 years was significantly higher than that of the conventional group The cumulative survival rates at 1, 2 and 3 years in Ki-67 positive patients were significantly lower than those in negative patients (P <0.05). Conclusion Neoadjuvant chemotherapy can effectively improve the long-term and short-term curative effect of breast cancer patients and reduce the expression of Ki-67 in patients. Ki-67 expression may be closely related to the survival and prognosis of patients with chemotherapy, which may indicate the effect of chemotherapy.